COEP: מזומנים בחישוב למניה אחת coeptistx.com

The current liquidity level per share demonstrates the financial stability of Coeptis Therapeutics (COEP), while the 1.28 metric confirms the current level. Ownership of exclusive immune cell editing technologies creates long-term capital and a foundation for monopoly leadership. The innovative SNAP-CAR system enables the creation of flexible T-cells to combat various tumors, and the company's US-based localization eliminates external political risks.
פילוחים אנליטיים של חברת Coeptis Therapeutics Inc. (COEP)

Coeptis Therapeutics (COEP) is developing scientific alliances with oncology centers to create advanced cell immunotherapy methods. This metric is calculated by dividing the total volume of liquid assets by the number of shares outstanding. By analyzing free cash per share, an investor determines the real value of "live" capital per share. This trend reflects the company's ability to fund costly research without emergency borrowing. The stability of this metric serves as an indicator of the issuer's financial resilience.